Kallyope scores $66 mln Series B
New York City-based Kallyope Inc, a biotechnology company focused on identifying therapeutic opportunities involving the gut-brain axis, has raised $66 million in Series B financing. The investors included Lux Capital, The Column Group, Polaris Partners, Illumina Ventures, Alexandria Venture Investments, Euclidean Capital and Two Sigma Ventures.
22 February 2018•1 min read
